Artiva Biotherapeutics (ARTV) Enterprise Value: 2023-2025
Historic Enterprise Value for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to -$150.4 million.
- Artiva Biotherapeutics' Enterprise Value fell 165.77% to -$150.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$893.6 million, marking a year-over-year decrease of 1671.15%. This contributed to the annual value of $59.4 million for FY2024, which is 39.21% up from last year.
- Latest data reveals that Artiva Biotherapeutics reported Enterprise Value of -$150.4 million as of Q3 2025, which was up 31.50% from -$219.5 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Enterprise Value ranged from a high of $228.6 million in Q3 2024 and a low of -$228.5 million during Q1 2025.
- Over the past 3 years, Artiva Biotherapeutics' median Enterprise Value value was -$50.9 million (recorded in 2023), while the average stood at -$36.2 million.
- As far as peak fluctuations go, Artiva Biotherapeutics' Enterprise Value skyrocketed by 446.98% in 2024, and later slumped by 400.33% in 2025.
- Over the past 3 years, Artiva Biotherapeutics' Enterprise Value (Quarterly) stood at $42.7 million in 2023, then surged by 39.21% to $59.4 million in 2024, then crashed by 165.77% to -$150.4 million in 2025.
- Its Enterprise Value was -$150.4 million in Q3 2025, compared to -$219.5 million in Q2 2025 and -$228.5 million in Q1 2025.